PEPTIDE COMPARISON

AOD-9604 vs Tesamorelin

A growth-hormone fragment with an unsuccessful obesity program compared with a narrow approved GHRH analog.

QUICK ANSWER

AOD-9604 vs Tesamorelin: the main difference.

Tesamorelin has stronger evidence for a specific HIV-lipodystrophy population. AOD-9604's obesity development did not establish persuasive efficacy, and neither peptide should be reframed as a general weight-loss substitute.

Decision field	AOD-9604	Tesamorelin
Human research	Phase 2 obesity development without persuasive efficacy	Multiple randomized trials in HIV lipodystrophy
Mechanism	Growth-hormone fragment	GHRH analog
FDA status	Not approved	Approved for one narrow indication
Weight-loss interpretation	Development did not establish an obesity medicine	Label explicitly is not general weight-loss management
2026 WADA	Prohibited at all times	Prohibited at all times

SOURCES

AOD-9604 vs Tesamorelin sources.

FDA / 2024AOD-9604 Pharmacy Compounding Advisory Committee briefingU.S. FDA FDA / 2026Bulk substances that may present significant safety risksU.S. FDA WADA / 20262026 Prohibited ListWorld Anti-Doping Agency FDA / 2025EGRIFTA WR prescribing informationU.S. FDA Human trial / 2010Pooled analysis of two Phase 3 tesamorelin trialsPubMed

AOD-9604 vs Tesamorelin: the main difference.

AOD-9604 vs Tesamorelin sources.

Questions related to AOD-9604 vs Tesamorelin.

Compare the next decision.